Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.

  title={Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.},
  author={Samit A Patrawala and Igor J. Puzanov},
  journal={Future oncology},
  volume={8 5},
Vemurafenib is a potent inhibitor of the mutated BRAF kinase. Phase I and II clinical trials of vemurafenib showed response rates of more than 50% in patients with metastatic melanoma and BRAF mutation. A Phase III study comparing vemurafenib with dacarbazine in 675 previously untreated patients revealed overall survival to be 84% (95% CI: 78-89) in the vemurafenib group and 64% (95% CI: 56-73) in the dacarbazine group. Vemurafenib was associated with a relative reduction of 63% in the risk of… CONTINUE READING